ENTROPY NEURODYNAMICS LIMITED — Director's Dealing 2020

Nov 9, 2020

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity:	Exopharm Limited
ABN:	78 163 765 991

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Ian E Dixon
Date of last notice	19 August 2019

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest
(including registered holder)	Altnia Holdings Pty Ltd <Dixon Family A/C>
Note: Provide details of the circumstances giving rise to the relevantinterest.	(Director and Controller)
Date of change	9 November 2020
No. of securities held prior to change	27,975,294 Fully Paid Ordinary Shares
Class	Unlisted Performance Rights
Number acquired	250,000
Number disposed	Nil
	Unlisted Performance Rights issued for nil
Value/ConsiderationNote: If consideration is non-cash, provide details and estimated	consideration pursuant to the Company’sPerformance Rights Plan as set out in the Notice
valuation	of EGM released to the ASX on 24 September
	2020 and approved by shareholders on 29
	October 2020.
	27,975,294 Fully Paid Ordinary Shares
No. of securities held after change
	250,000 Unlisted Performance Rights

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Nature of change

Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback

Issue of Unlisted Performance Rights pursuant to the Company’s Performance Rights Plan as approved by Shareholders on 29 October 2020

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

==> picture [434 x 299] intentionally omitted <==

----- Start of picture text ----- Detail of contract N/ANature of interest N/AName of registered holderN/A(if issued securities)Date of change N/ANo. and class of securities to whichinterest related prior to changeN/ANote: Details are only required for a contract inrelation to which the interest has changedInterest acquired N/AInterest disposed N/AValue/ConsiderationNote: If consideration is non-cash, provide details N/Aand an estimated valuationInterest after change N/A----- End of picture text -----

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed No above traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow the N/A trade to proceed during this period? If prior written clearance was provided, on what date was N/A this provided?

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011